Overview

Intra-arterial Chemotherapy for Retinoblastoma

Status:
Recruiting

Trial end date:
2024-05-31

Target enrollment:

Participant gender:

Summary

Children with retinoblastoma who may benefit from intra-arterial chemotherapy will receive up to 3 doses of melphalan and will be assessed for feasibility, toxicity, and response.

Phase:

Phase 1

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

Melphalan